Protagonist, Takeda's profit sharing deal under spotlight after Phase 3 blood disorder trial win

Max Gelman

Senior Editor

Protagonist Therapeutics reported a clean Phase 3 win on Monday for rusfertide — its rare blood disorder therapy — putting it on track for a fourth-quarter FDA …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Protagonist, Takeda's profit sharing deal under spotlight after Phase 3 blood disorder trial win

Max Gelman

Senior Editor

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

After Phase 3 depression setback, Neumora pauses two trials to make changes, scraps another

Novo Nordisk signs $354M partnership with AI-guided biotech for ‘risky’ new metabolic mechanisms

ADCs from a decade-old Singapore biotech find new life with $187M

AbbVie finally enters obesity race with $350M upfront for Gubra’s amylin

Trump blog: Top HHS spokesperson resigns within weeks of being sworn in

The perfect storm: Why everything is in place for 2025 to be the year of GxP AI

Pro­tag­o­nist, Takeda's prof­it shar­ing deal un­der spot­light af­ter Phase 3 blood dis­or­der tri­al win

Senior Editor

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Protagonist, Takeda's profit sharing deal under spotlight after Phase 3 blood disorder trial win